Science Translational Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2024-08-05 ms2000001292895178 来自江苏省

Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。

87 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2025-01-25 ms4000000247112478

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：转化
经验分享：难

28 0

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2025-01-23 ms9000001641915653 来自湖北省

审稿速度:6.0 | 投稿命中率:25.0
经验分享：多尝试，多做扎实工作

22 0

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2021-01-26 ms4000001898750078

有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂

623 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2024-10-12 dr_NEO 来自山东省

请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2024-11-24 ms9000000999973246 来自安徽省

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;生物学;分子机制
经验分享：投稿周期很长

27 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2024-10-29 Charlo 来自安徽省

偏重的研究方向：转化医学;医学
经验分享：To review 快四个月了，是生是死给个准话。

11 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2024-06-01 12287059m09暂无昵称来自湖北省

to advisor是什么状态？

287 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2019-06-21 DgYr7579

审稿速度:1.0 | 投稿命中率:25.0
经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。

282 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218626, encodeId=1be72218626ea, content=Science家族的王牌期刊，对标Cell家族的Cancer cell和Nature家族中的Nature Cell biology等老牌经典大子刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af579397449, createdName=ms2000001292895178, createdTime=Mon Aug 05 19:23:02 CST 2024, time=2024-08-05, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2249621, encodeId=a0a122496219d, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：转化 经验分享：难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa988124394, createdName=ms4000000247112478, createdTime=Sat Jan 25 19:49:58 CST 2025, time=2025-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249274, encodeId=635722492e4ca, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：多尝试，多做扎实工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2388501668, createdName=ms9000001641915653, createdTime=Thu Jan 23 10:02:04 CST 2025, time=2025-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=919994, encodeId=f00f91999487, content=有没有小伙伴了解修回到接收的时间呀。小修revise之后，经历了两轮to review 到 under evaluation。本来一审只安排了两个reviewer，意见都很积极，以为会比较顺利，然而现在卡在under evaluation又不动了😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=623, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b5455877, createdName=ms4000001898750078, createdTime=Tue Jan 26 13:38:16 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230550, encodeId=02a72230550ab, content=请问STM是必须所有作者同意才能进行下一步吗？under evaluation分配编辑好几天了，一直没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211125/3ed6e6b85cb94850bc6d5c9196d9515b/fa7ea09f297a4ff3ac3a8b97cd364368.jpg, createdBy=e2885122441, createdName=dr_NEO, createdTime=Sat Oct 12 19:33:39 CST 2024, time=2024-10-12, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2238988, encodeId=72ba223898864, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;生物学;分子机制 经验分享：投稿周期很长, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=263c5597393, createdName=ms9000000999973246, createdTime=Sun Nov 24 23:42:28 CST 2024, time=2024-11-24, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2234004, encodeId=7258223400436, content=偏重的研究方向：转化医学;医学 经验分享：To review 快四个月了，是生是死给个准话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Tue Oct 29 22:14:53 CST 2024, time=2024-10-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2207758, encodeId=43fa220e758e0, content=to advisor是什么状态？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6b322338771, createdName=12287059m09暂无昵称, createdTime=Sat Jun 01 07:53:10 CST 2024, time=2024-06-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=572652, encodeId=fdbe5e265207, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：最近投了一篇，提交完就是received，大概一两天之后是under evaluation，这时候也能看到分配的编辑名字了，然后等了5天，reject了，没有送外审。编辑们还是很严格的，能送外审就是对文章的肯定了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccd32316825, createdName=DgYr7579, createdTime=Fri Jun 21 09:04:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143145, encodeId=294421431452e, content=请问一下投这个杂志后是必须所以作者都要同意认证吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Fri Jun 16 14:55:24 CST 2023, time=2023-06-16, status=1, ipAttribution=北京)]

2023-06-16 默默0606 来自北京

请问一下投这个杂志后是必须所以作者都要同意认证吗？

254 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务